Clarivate Plc (CLVT) is a global information-services and data-analytics company whose products—including Web of Science, Derwent and CompuMark—serve intellectual property, life sciences and academic customers. The stock has been one of the market's more heavily debated names, with a wide gap between bullish and bearish analyst views. That gap is at the heart of the question investors are asking: can CLVT reach $2.80?
Six current, attributable analyst price targets were reviewed to establish the central target. The individual targets are: Morgan Stanley at $1.50 (Underweight, late October 2026), Barclays at $2.00 (Underweight), Citi at $2.50 (Neutral), Goldman Sachs at $2.60 (Neutral), RBC Capital at $3.00 (Sector Perform), and Stifel at $5.00 (Buy). The calculated arithmetic mean is approximately $2.77, rounded to a clean $2.80.
The range of $1.50 to $5.00 is exceptionally wide, which signals genuine disagreement rather than a uniform consensus. Only one of the six firms carries a bullish rating, while two are outright bearish and three are neutral. Notably, most firms trimmed their targets on July 30, 2026 after second-quarter results, and Morgan Stanley resumed coverage with a cautious $1.50 target in late October 2026. The average analyst price target is best read as a reference point, not a forecast of where the stock will trade.
With the latest verified price near $1.66, the move to $2.80 represents roughly 69% upside—a very large move. Clarivate's market capitalization has contracted to roughly $1.06 billion, while trailing-twelve-month revenue stands near $2.41 billion and the company has posted a net loss of about $334 million over that period. The forward P/E (price-to-earnings ratio) is compressed at roughly 2.4 times adjusted earnings, but total debt of about $4.26 billion keeps the enterprise value near $5.1 billion, well above the equity value.
A path toward $2.80 would likely require a combination of stabilizing organic revenue, successful execution of the company's "Value Creation Plan," and a meaningful re-rating of the shares. Given the stock's 52-week range of about $1.42 to $3.87, a return toward the $2.80 area would still sit below the prior-year high.
Clarivate's most defensible attribute is cash generation, with levered free cash flow near $465 million over the past twelve months. The company has used buybacks to reduce its share count, and it is simplifying its portfolio—including a divestiture of the Life Sciences & Healthcare segment for roughly $600 million to Altaris. If that transaction reduces leverage and sharpens focus on core IP and academic data franchises, it could support a higher valuation.
Bullish analysts, led by Stifel's $5.00 target, argue the shares are inexpensive on free cash flow and that the reset expectations leave room for upside if organic growth inflects. A stabilization of subscription revenue and successful rollout of AI-enabled products such as Web of Science Research Intelligence are key swing factors.
The bearish case is substantial. Revenue has been declining, with trailing-twelve-month revenue down roughly 3.5% year over year, and analysts broadly expect further contraction. The more cautious firms—Morgan Stanley and Barclays—cite modest organic growth, pricing-power limits, and execution risk. Artificial intelligence is a genuine threat, as cheaper generative-AI tools can substitute for parts of Clarivate's information and workflow products.
Elevated debt relative to equity, persistent net losses, and high short interest of roughly 7% of shares outstanding all add pressure. If organic revenue keeps shrinking or the restructuring fails to improve margins, the shares could remain anchored near current levels or lower.
Clarivate trades below both its 50-day moving average near $1.81 and its 200-day moving average near $2.22, keeping the near-term trend tilted lower. The 52-week range of roughly $1.42 to $3.87 makes $1.42 an important support level, while $2.20 to $2.30—the area of the 200-day average—is an initial resistance zone that would need to be reclaimed before the $2.80 target becomes relevant. Round-number levels around $2.00 and $2.50 may also act as psychological markers.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may differ. Investors should watch upcoming quarterly results, any guidance on organic revenue and free cash flow, further analyst target revisions, progress on the portfolio divestitures and deleveraging, and the competitive impact of AI on subscription demand. Changes in the share count through buybacks and any shift in short interest are also worth monitoring.
For traders seeking a more systematic view, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Exploring these AI-generated signals can complement the fundamental and technical picture outlined above.
The $2.80 central target is a calculated average of six analyst price targets spanning a very wide $1.50 to $5.00 range. Reaching it would require a gain of roughly 69% from current levels—a very large move that hinges on a fundamental turnaround Clarivate has not yet delivered. The bull case rests on free cash flow, deleveraging, and a potential re-rating; the bear case points to declining revenue, AI disintermediation, and execution risk. With only one bullish rating among the group and most firms holding neutral or cautious stances, the path to $2.80 depends heavily on evidence of stabilized organic growth and successful restructuring. Investors should monitor quarterly results and analyst revisions closely rather than treat the average target as a foregone conclusion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CLVT has been loosely correlated with FLYW. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CLVT jumps, then FLYW could also see price increases.
| Ticker / NAME | Correlation To CLVT | 1D Price Change % | ||
|---|---|---|---|---|
| CLVT | 100% | -1.95% | ||
| FLYW - CLVT | 61% Loosely correlated | -2.20% | ||
| PSFE - CLVT | 56% Loosely correlated | -9.57% | ||
| PAY - CLVT | 51% Loosely correlated | -2.67% | ||
| XRX - CLVT | 50% Loosely correlated | -0.65% | ||
| AI - CLVT | 49% Loosely correlated | -9.06% | ||
More | ||||
| Ticker / NAME | Correlation To CLVT | 1D Price Change % |
|---|---|---|
| CLVT | 100% | -1.95% |
| Technology Services category (392 stocks) | 12% Poorly correlated | -3.94% |